Y-mAbs Therapeutics, Inc.
YMAB
$4.71
-$0.02-0.42%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -587.25% | 9.67% | -46.76% | -3.74% | -185.39% |
| Total Depreciation and Amortization | -36.65% | -27.98% | -31.70% | -12.64% | -30.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 170.58% | 7.10% | 11.31% | -10.52% | -34.63% |
| Change in Net Operating Assets | 87.04% | -298.57% | 392.89% | 88.57% | 29.87% |
| Cash from Operations | 76.73% | -697.09% | 106.29% | 73.51% | 7.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 886.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 886.00% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -300.00% | -- | -92.86% | 111.11% | 101.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.81% | -623.77% | 143.58% | 78.01% | 9.47% |
